cyrilzakka/clinical-trials huggingface dataset:
Reliability and Validity of the Six-Spot Step Test After Total Hip Arthroplasty

This study aims to assess the SSST's validity, reliability, and ability to differentiate between high and low fall risk individuals in THA patients. Establishing the SSST as a valid and reliable tool will help manage rehabilitation and apply timely interventions for THA patients.

Total hip arthroplasty (THA) is a common surgery for patients with advanced hip osteoarthritis, aiming to reduce pain and improve function. However, THA patients often experience difficulties in mobility tasks, such as walking, stair climbing, and standing up, even years after surgery. These functional impairments increase the risk of falls, highlighting the need for effective clinical tests to assess balance and mobility. Identifying factors contributing to balance dysfunction and implementing appropriate rehabilitation are crucial for improving quality of life.

The Six-Spot Step Test (SSST), developed by Nieuwenhuis et al., is a quick and easy test that evaluates balance and mobility in daily life activities. However, its validity and reliability in THA patients have not been studied. This research aims to assess the SSST's validity, reliability, and ability to differentiate between high and low fall risk individuals in THA patients. Establishing the SSST as a valid and reliable tool will help manage rehabilitation and apply timely interventions for THA patients.

Eligibility Criteria:
Inclusion Criteria:

* Underwent primary unilateral Total Hip Arthroplasty (THA)
* Surgery performed using the posterolateral approach
* At least six months of postoperative follow-up

Exclusion Criteria:

* Patients who underwent bilateral or revision THA
* History of additional lower limb surgery
* Body mass index (BMI) greater than 40 kg/m²
* Neurological, orthopedic, or systemic disorders that could impair gait or balance
Weight Loss Effect on Circulating Liver Enzymes

To investigate weight loss effect with mild calorie restriction on circulating levels of liver enzymes in nondiabetic and overweight subjects with high visceral fat area \[visceral fat area (VFA) at L4 ≥ 100 cm²\].

A 12-week randomized, placebo-controlled study was conducted on 80 nondiabetic and overweight subjects with high VFA. The participants divided into two groups: 12-week mild calorie restriction (a 300 kcal/day intake reduction, n=40) or no treatment (control, n=40). The randomization was according to computer-generated block randomization (placebo:test = 1:1). Before and after intervention period, venous blood samples were obtained from the subjects, and biochemical parameters including circulating liver enzymes were measured.

Eligibility Criteria:
Inclusion Criteria:

* Able to give informed consent
* 20-60 years old
* Males and females
* Overweight (25.0 kg/m²≤ BMI \<30 kg/m²)
* Absence of pregnancy or breast-feeding
* Stable body weight (body weight change \<1kg for 3 months before screening)
* High visceral fat (VFA) at L4 (VFA at L4 ≥100 cm²)
* Without hypertension, type 2 diabetes, cardiovascular disease, or thyroid disease
* No use medication affecting body weight, energy expenditure, or glucose control for the last 6 months

Exclusion Criteria:

* Prior history of Cushing syndrome or malignancy
* Prior history of liver disease including chronic viral hepatitis, autoimmune hepatitis, primary biliary cirrhosis, or drug-induced liver disease
* Excess alcohol intake (based on WHO standard)
* History of intentional reduction in weight in the preceding 6 months
Platelet-Rich Fibrin and Hyaluronic Acid vs. Hyaluronic Acid Injection for TMJ Internal Derangement

Injectable PRF technology, according to literature evidence, ensures the release of growth factors over time which play a major role in the release of regenerative factors for tissue repair after injection, while HA is an anti-inflammatory medication that can provide rapid relief from pain and inflammation in joints. It is a major natural component of synovial fluid that plays an important role in lubrication of synovial tissues However, its effect is typically temporary, and it doesn\&#39;t promote tissue healing or regeneration.

For this reason, this protocol has been designed with the aim to investigate whether injection in the injection i- pRF with HA can achieve the same improvements of pain and function, compare this technique with arthrocentesis.

One group will receive arthrocentesis only, the second group will receive 1 mm hyaluronic acid injection and the third group will receive a mixture of 1 ml hyaluronic acid, 1 ml of injectable PRF

Eligibility Criteria:
Inclusion Criteria:

* Presence of TMJ-ID related symptoms.
* Patients suffering from TMJ internal derangement (disc displacement with reduction).
* Age limit between 20 and 45years so Patient less than 21years will need assent form ...as well as written informed consent from the parents \\guardians.
* No previous TMJ surgical procedures
* Acquisition of informed consent.
* Cooperative patient
* Patients free from any systemic disease that may affect the procedure.

Exclusion Criteria:

* Previous malignant head and neck neoplasms.
* Patients suffering from inflammatory or connective tissue systemic diseases.
* Neurologic disorders.
* History of bony or fibrous adhesion
* Gross mechanical restrictions and condylar fractures, previous TMJ surgery, TMJ ankylosis, or acute infection.
* Patients maintained on anti-coagulants, muscle relaxants, non-steroidal anti-inflammatory drugs within 48 h preoperatively, corticosteroid injection at treatment site within one month or systemic use of corticosteroids within 2 weeks was also excluded in this study.
* Uncooperative patient
* Pregnant and lactating female.
* Patients with systemic diseases (e.g., rheumatoid arthritis, psoriatic arthritis, or juvenile arthritis), and those who had shown symptoms of hypersensitivity to the HA solution.
Effectiveness and Safety of Electro-acupuncture for Mild-to-moderate Perimenopausal Depression

Main objective: to compare the effects of electro-acupuncture and escitalopram oxalate tablets on mild-to-moderate perimenopausal depression, and to evaluate the safety of electroacupuncture stimulation.


Eligibility Criteria:
Inclusion Criteria:

* Conforms to the diagnosis standard of STRAW-10 for perimenopause, conforms to the diagnosis standard of The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) for depression, and conforms to the diagnosis standard of The International Statistical Classification of Diseases and Related Health Problems 10th Revision (ICD-10) F32.0(mild depression) or F32.1(moderate depression);
* Fisrt attack during perimenopausal period;
* HAMD-17 score \>7 and \<23;
* Age ≥45 to ≤55;
* No hormone replacement therapy (HRT) or no antidepressant 3 months before into the group;
* Sign the consent consent, volunteered for this study

Exclusion Criteria:

* Fail to rule out the possibility of suicide in depression factor of The Symptom Checklist (SCL-90);
* Application of estrogen, progesterone, selective serotonin reuptake inhibitors (SSRIs), soybean isoflavone, vitamin E or black cohosh in recent 4 weeks;
* Allergic to citalopram or escitalopram tablets;
* Taken the non selective, irreversible inhibitor of monoamine oxidase (MAOIs) in recent 2 weeks;
* Taken linezolid, pimozide, tryptophane,tramadol, triptans or other drugs that may cause drug adverse reactions in recent 2 weeks;
* Patient with prolongation of the QT interval or congenital long QT syndrome
* Taken herbs or products that contain isatin, pilose antler, hawthorn, fleeceflower root, common St.John's wort herb, hypericin;
* Ovarian dropsy or hysteromyoma with more than 4cm diameter, oophorectomy, or hysterectomy;
* Mandatory indications of hormonotherapy, such as surgery-induced menopause or osteoporosis;
* Patient with history of radiotherapy or chemotherapy, or undergoing radiotherapy or chemotherapy;
* Vaginal bleeding of undetermined origin;
* Patient with coagulation disorders, or taking anticoagulants such as Warfarin, or heparin;
* Patient with skin diseases, such as eczema,or psoriasis;
* Serious hepatic insufficiency or serious renal inadequacy;
* Uncontrolled hypertension, diabetes, or thyroid disease;
* Diabetic neuropathy, or malignant tumor;
* Pregnancy intention, in pregnancy or lactation;
* Regular use of sedative and anti anxiety drugs;
* The long-term smoking and/or drinking;
* Having Pacemaker or artificial joint；
* Electrolyte is disorder, serious heart disease or other potential life-threatening disease patients;
* Compliance may be poor or fear of acupuncture.
Endolumenal Partial Myotomy for the Treatment of Esophageal Achalasia

Achalasia is a primary esophageal motility disorder where the lower esophageal sphincter fails to relax in response to swallowing with no well understood underlying cause. Surgical myotomy represents an appropriate therapeutic option. The purpose of this study is to evaluate flexible endoscopic myotomy, a novel therapeutic approach to overcome the need for invasive surgery.

In this study, the investigators propose the use of a recent endolumenal technique for partial myotomy in patients suffering from esophageal achalasia.

Under general anesthesia patients will have upper endoscopy. Submucosal injection and mucosal incision is created for entry into the submucosal space. A submucosal tunnel is then created using a needle knife or blunt dissection as appropriate. Dissection will continue distally beyond the lower esophageal sphincter. The inner circular muscle fibers will then be divided to achieve an adequate myotomy length. The mucosal entry is then closed appropriately.

Results will be compared to historical data of conventional Heller myotomies.

Eligibility Criteria:
Inclusion Criteria:

* Candidate for elective Heller myotomy
* Ability to undergo general anesthesia
* Ability to give informed consent

Exclusion Criteria:

* Previous mediastinal or esophageal surgery
* Contraindications for EGD
Repetitive Transcranial Magnetic Stimulation on Dysphagia in the Stroke Patient

Participants suffered from acute stroke with dysphagia in single hospital who were determined by CT/MRI and clinical evaluation. Current project will recruit participants and randomize into two groups.One group will receive NMES, traditional swallowing therapy and rTMS therapy five times per week for 2 weeks ; Another group will receive NMES and traditional swallowing therapy with shame rTMS five times per week for 2 weeks. FEES and SSA were used for evaluated swallowing function before the therapy and after 2 weeks therapy.

Participants suffered from acute stroke with dysphagia in single hospital who were determined by CT/MRI and clinical evaluation. The aim of this study is to compare the effects of rTMS, NMES and conventional swallowing therapy to those of sham rTMS, NMES and conventional swallowing therapy. One group will receive NMES, to sham One group will receive NMES,traditional swallowing therapy and rTMS therapy five times per week for 2 weeks ; Another group will receive NMES and traditional swallowing therapy with shame rTMS five times per week for 2 weeks. MEP character, FEES, degrees of dysphagia, FOIS, and SSA were used for evaluated swallowing function before the therapy and after 2 weeks therapy.

Eligibility Criteria:
Inclusion Criteria:

1. stroke
2. Onset time at least for one week，area not be limited.
3. Patient was first time stroke patient without obvious infection condition.
4. Patients with dysphagia in the stroke who were diagnosed by neurologist and CT/MRI in our institute. Patient was clear with adequate motivation and could cooperate the whole therapy and FEES evaluation.

Exclusion Criteria:

1. Lower motor neuron disease, such as autonomic dysreflexia, facial palsy, hyhoid muscle denervation.
2. Mental status unstable, mental retardation, schizophrenia, bipolar disease were be excluded.
3. Metal implantation of head, ventroperotoneal shunt or any seizure history, pacemaker, as well as head and neck cancer.
4. Allergy to specific subjects
5. Cognition impairment
6. Alcohol or drugs abuse
7. Afraid of the noise of rTMS.
Obstacles to Deprescribing Among French Patients Over 75 Years of Age Treated in the Geriatric Hospital Network

The aim of this study is to highlight action guidelines to encourage acceptance of deprescribing in people over 75 years of age: training, therapeutic education, post-prescription follow-up, specific patient pathways, specific consultations or even the integration of an advanced practice nurse in this process.

For several years now, the proportion of senior citizens in our country has been rising steadily. There are now 6.4 million people over the age of 75 in France.

It is therefore important to take into account the needs and specificities of this part of the population. One of its particularities is polypathology. Indeed, from the age of 70 onwards, 93% of elderly subjects have at least 2 diseases and 85% have at least 3. This polypathology will lead to a large number of different prescribers with an increased risk of having more than 5 molecules in their personal treatment. This is known as polypharmacy.

In the elderly, polypharmacy is harmful. It increases the risk of adverse effects and drug interactions. In France, 20% of patients over 75 years old and 25% of those over 85 years old consult the emergency room because of adverse drug reactions.

The literature shows that we can act on these adverse events by "deprescribing". De-prescribing is defined as intentionally stopping the prescription of an unnecessary or potentially dangerous drug for a patient.

The expected benefit for the patient is to reduce the iatrogenic risks induced by treatments that would no longer be useful for him/her or that have a negative benefit/risk balance. To achieve this objective, the patient must understand this risk, understand the benefit he or she can derive from it and be an actor in this process.

For carers, the expected benefit is greater involvement of the patient in the process, better adherence to the approach, which can be organised and carried out in a safer way.

Eligibility Criteria:
Inclusion Criteria:

* Patients aged 75 years and over
* Hospitalized in geriatric short-stay or geriatric rehabilitation units
* Patients who did not object to participation in the study

Exclusion Criteria:

* Patient refusal
* Patients not able to understand and fill in the questionnaire: Cognitive disorders, Confusion, Unstable clinical state, Sensory disorders, not speaking French.
* Patient under protective supervision (guardianship or curatorship)
REDucing Hot FLASHes in Women Using Endocrine Therapy.

The goal of this randomized intrapatient cross-over study is to assess the efficacy of oxybutynin versus venlafaxine in reducing hot flashes in women using endocrine therapy after breast cancer.

The objectives it aims to answer are:

* To assess the efficacy of oxybutynin versus venlafaxine in reducing hot flashes in women using endocrine therapy after breast cancer
* To assess side effects of oxybutynin versus venlafaxine.
* To assess the personal preference of women for oxybutynin versus venlafaxine in reducing hot flashes.
* To assess quality of life of women when reducing hot flashes in women using endocrine therapy after breast cancer.

Participants will fill-out a patient diary during 15 weeks total on a daily basis and receive an (online) questionnaire three times total.

Researchers will compare two groups (venlafaxine group versus oxubutynine group) to assess its efficacy concerning hot flashes.


Eligibility Criteria:
Inclusion Criteria:

* Pre-, peri- or postmenopausal women of 18 years or above;
* Indication for endocrine therapy and already started with tamoxifen, aromatase inhibitors or luteinizing hormone-releasing hormone analogues for at least 4 weeks and planning to continue for the duration of the study;
* Experiencing hot flashes with a minimum of 14 per week for at least 1 month and desire to start a pharmacologic intervention.

Exclusion Criteria:

* Pregnant;
* Breast feeding;
* Patients who receive chemotherapy or immunotherapy/HER2 antibodies within the prior 8 weeks, and patients scheduled for chemotherapy during the study period;
* Palliative setting;
* Use of venlafaxine or any other antidepressants, also including St. John's wort within the previous year;
* Creatinine clearance \< 30 ml/min;
* Liver cirrhosis;
* Use of gabapentin and/or calcium channel antagonists within 2 weeks of study entry;
* Use of oxybutynin before study entry;
* Use of any other substances or therapies for the treatment of hot flashes, for instance acupuncture.
Efficacy of Character Strengths Intervention in Enhancing Character Strengths and Self-esteem Among Adolescents

The goal of this study is to better understand the experiences of adolescents with physical disabilities and assess the effectiveness of a Character Strengths Intervention (CSI) in improving their self-esteem, character strengths, and mental health. We will also compare these outcomes between two groups: one receiving the intervention and the other not receiving any treatment.

Main Research Questions:

How do adolescents with physical disabilities perceive their self-esteem, character strengths, and mental health, including psychological adjustment, psychological distress, psychological wellbeing, life satisfaction, and resilience? Can the Character Strengths Intervention (CSI) enhance the self-esteem, character strengths, and mental health (psychological adjustment and distress) of adolescents with physical disabilities?

Study Tasks:

Participants, who are adolescents aged 12-18 years, will be asked to provide informed consent to participate in the study.

They will complete questionnaires to assess their self-esteem, character strengths, and mental health as a pre-assessment.

Participants in the intervention group will undergo the Character Strengths Intervention (CSI), which includes activities like exploring character strengths, writing gratitude letters, and practicing fresh look meditation, among others.

After the intervention, participants will complete post-assessment questionnaires to measure changes in self-esteem, character strengths, and mental health.

There will be a control group that does not receive any treatment.

Comparison Group:

Researchers will compare the outcomes between the intervention group, who received the Character Strengths Intervention (CSI), and the control group, who did not receive any treatment. This will help us determine if the intervention had a significant impact on self-esteem, character strengths, and mental health outcomes for adolescents with physical disabilities.


Eligibility Criteria:
Inclusion Criteria:

1. Adolescents with physical disability
2. Adolescents with physical disability in the age range 11-18
3. Rural and urban residences
4. Urdu, Englishspeaking
5. Rawalpindi and Islamabad special education schools

Exclusion Criteria:

1. Adolescents under age 11 and above 18
2. Adolescents whose parents, teachers, or themselves would not be agreed and signed informed consent to participate in the study would be excluded
3. Adolescents with physical disability such as:

   * Sensory disability (mute and Fully/partial-visual impairment) impairment
   * Hearing impairment
   * Deaf-blindness
   * And intellectual and cognitive impairment
4. Adolescents with severe psychiatric and major medical issues -
Histological/ Immunohistological and Molecularpathological Types of Epulides and Central Giant Cell Lesions of the Jaws

This retrospective study will evaluate the patient collective of the Division of Oral Surgery and Orthodontics, Department of Dental Medicine and Oral Health and of the Division of Cranio-Maxillofacial Surgery at the Medical University Graz concerning the frequency of epulis/giant cell lesion or underlying differential diagnoses and immunophenotypes as well as the resulting treatment methods and their success and compare these with international results

Different histopathological differential diagnoses can underlay the clinical presentation of an epulis. Often the immunophenotype of these lesions is of particular importance. This also holds for the the central giant cell lesion.

This study will evaluate the patient collective of the Division of Oral Surgery and Orthodontics, Department of Dental Medicine and Oral Health and of the Division of Cranio-Maxillofacial Surgery at the Medical University Graz concerning the frequency of epulis/giant cell lesion or underlying differential diagnoses and immunophenotypes as well as the resulting treatment methods and their success and compare these with international results.

This is a retrospective study using electronic patient records, written records, operative reports of the Division of Oral Surgery and Orthodontics, Department of Dental Medicine and Oral Health and of the Division of Cranio-Maxillofacial Surgery at the Medical University Graz in the period from 1986 to March 2018. It is intended to gather the data within 12 months and analyze statistically subsequently.

Eligibility Criteria:
Inclusion Criteria:

* existence of a medical history and a histopathological finding of the surgical specimen
* patients treated in the outpatient clinic for diseases of oral mucosa of the Division of Oral Surgery and Orthodontics, Department of Dental Medicine and Oral Health and of the Division of Cranio-Maxillofacial Surgery at the Medical University Graz between 1986 and March 2018

Exclusion Criteria:

* absence of a medical history or a histopathological finding.
Evaluation of the Influence of Statins and Proton Pump Inhibitors on Clopidogrel Antiplatelet Effects

There is conflicting evidence in the literature suggesting that the use of proton pump inhibitors (PPIs), and/or some statins can interfere with clopidogrel antiplatelet effect and result in adverse cardiovascular outcomes in patients treated with coronary artery stents and dual antiplatelet therapy.

The primary aim of the study is to determine the effect of various currently used PPI on platelet aggregation in patients undergoing percutaneous coronary intervention (PCI) and treated with dual antiplatelet therapy.

The secondary aim of the study is to evaluate how statins and 2C19\*2 polymorphism modulate the effect of PPI on clopidogrel efficacy.


Eligibility Criteria:
Inclusion Criteria:

* Subject must be 18 years of age or older
* Bare metal stent implantation
* Discharged with dual antiplatelet therapy for at least 60 days
* Written informed consent

Exclusion Criteria:

* Patients who do not consent to participate in the study
* Premenopausal women not using contraceptive methods or without a negative pregnancy test in the past week
* Patients treated or planned to be treated with oral anticoagulants
* Present treatment with or clear indication for treatment with a PPI or H2 antagonists
* Allergy or intolerance to study medications including ranitidine, Proton pump inhibitors, atorvastatin, rosuvastatin, aspirin and/or clopidogrel
* Patient treated with a strong CYP2C19 interacting drug
* History of a bleeding diathesis, or evidence of active abnormal bleeding within 30 days before enrollment
* History of intracranial hemorrhage or intracranial surgery in the last 3 months
* History of gastro-intestinal ulcers in the last 3 months
* Any serious illness or any condition that the investigator feels would influence the impact of this therapy on the subject
* Known platelet count \< 100000/mm3 at time of enrollment or within 24 hours prior to enrollment